A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

BACKGROUND: Optimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy. PATIENTS AND METHODS: Patients with bone metastases from breast or castration-resistant prostate cancer (CRPC), w...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemons, Mark, Ong, Michael, Stober, Carol, Ernst, Scott, Booth, Christopher, Canil, Christina, Mates, Mihaela, Robinson, Andrew, Blanchette, Phillip, Joy, Anil Abraham, Hilton, John, Aseyev, Olexiy, Pond, Gregory, Jeong, Ahwon, Hutton, Brian, Mazzarello, Sasha, Vandermeer, Lisa, Kushnir, Igal, Fergusson, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532126/
https://www.ncbi.nlm.nih.gov/pubmed/33023785
http://dx.doi.org/10.1016/j.ejca.2020.08.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532126/
https://www.ncbi.nlm.nih.gov/pubmed/33023785
http://dx.doi.org/10.1016/j.ejca.2020.08.019

Ejemplares similares